Sangamo Biosciences reported $122.36M in Current Liabilities for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Alnylam Pharmaceuticals ALNY:US USD 772.79M 115.11M
Amgen AMGN:US USD 15.69B 1.36B
Avrobio Inc AVRO:US USD 16.19M 3.41M
Bayer BAYN:GR EUR 33.17B 471M
Biogen BIIB:US USD 3.93B 1.09B
Biomarin Pharmaceutical BMRN:US USD 521.02M 56.29M
Bluebird Bio BLUE:US USD 126.73M 22.13M
Gilead Sciences GILD:US USD 11.24B 814M
GlaxoSmithKline GSK:LN GBP 22.81B 1.86B
Intercept Pharmaceuticals ICPT:US USD 221.58M 70.16M
IONIS PHARMACEUT IONS:US USD 283.45M 15.64M
Karyopharm Therapeutics KPTI:US USD 61.76M 780K
Novartis NOVN:VX USD 28.16B 514M
Omeros OMER:US USD 39.51M 1.01M
Regulus Therapeutics RGLS:US USD 10.52M 4.69M
Roche Holding ROG:VX 27.41B 11.01B
Sangamo Biosciences SGMO:US USD 122.36M 2.37M
Sarepta Therapeutics SRPT:US USD 602.92M 57.35M
Ultragenyx Pharmaceutical RARE:US USD 227.36M 6.72M
Vertex Pharmaceuticals VRTX:US USD 2.61B 53.1M
Ziopharm Oncology ZIOP:US USD 32.87M 6.09M